Idarubicin-loaded drug-eluting microspheres transarterial chemoembolization for intermediate stage hepatocellular carcinoma: safety, efficacy, and pharmacokinetics

1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2024. [cited 2024 Feb 1]. Available at: https://gco.iarc.who.int/today FerlayJ ErvikM LamF LaversanneM ColombetM MeryL PiñerosM Global Cancer Observatory: cancer today Lyon, France International Agency for Research on Cancer 2024 [cited 2024 Feb 1]. Available at: https://gco.iarc.who.int/today Search in Google Scholar

2. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022; 400: 1345–62. doi: 10.1016/S0140-6736(22)01200-4 VogelA MeyerT SapisochinG SalemR SaborowskiA Hepatocellular carcinoma Lancet 2022 400 1345 62 10.1016/S0140-6736(22)01200-4 Open DOISearch in Google Scholar

3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182–236. doi: 10.1016/j.jhep.2018.03.019 European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatocellular carcinoma J Hepatol 2018 69 182 236 10.1016/j.jhep.2018.03.019 Open DOISearch in Google Scholar

4. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76: 681–93. doi: 10.1016/j.jhep.2021.11.018 ReigM FornerA RimolaJ Ferrer-FàbregaJ BurrelM Garcia-CriadoÁ BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update J Hepatol 2022 76 681 93 10.1016/j.jhep.2021.11.018 Open DOISearch in Google Scholar

5. Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open 2023; 8: 101567. doi: 10.1016/j.esmoop.2023.101567 DucreuxM Abou-AlfaGK Bekaii-SaabT BerlinJ CervantesA de BaereT The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022 ESMO Open 2023 8 101567 10.1016/j.esmoop.2023.101567 Open DOISearch in Google Scholar

6. Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 2019; 72: 28–36. doi: 10.1016/j.ctrv.2018.11.002 RaoulJL FornerA BolondiL CheungTT KloecknerR de BaereT Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence Cancer Treat Rev 2019 72 28 36 10.1016/j.ctrv.2018.11.002 Open DOISearch in Google Scholar

7. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474–81. doi: 10.1016/j.jhep.2006.10.020 VarelaM RealMI BurrelM FornerA SalaM BrunetM Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 2007 46 474 81 10.1016/j.jhep.2006.10.020 Open DOISearch in Google Scholar

8. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinon A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 2010; 33: 41–52. doi: 10.1007/s00270-009-9711-7 LammerJ MalagariK VoglT PilleulF DenysA WatkinonA Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Interv Radiol 2010 33 41 52 10.1007/s00270-009-9711-7 Open DOISearch in Google Scholar

9. Boulin M, Guiu S, Chauffert B, Delhom E, Schmitt A, Hillon P, et al. Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anticancer Drugs 2011; 22: 741–8. doi: 10.1111/apt.12746 BoulinM GuiuS ChauffertB DelhomE SchmittA HillonP Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma Anticancer Drugs 2011 22 741 8 10.1111/apt.12746 Open DOISearch in Google Scholar

10. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 1993; 24: 275–88. doi: 10.2165/00003088-199324040-00002 RobertJ Clinical pharmacokinetics of idarubicin Clin Pharmacokinet 1993 24 275 88 10.2165/00003088-199324040-00002 Open DOISearch in Google Scholar

11. Guiu B, Hincapie G, Thompson L, Wu Y, Boulin M, Cassinotto C, et al. An in vitro evaluation of four types of drug-eluting embolics joaded with idarubicin. J Vasc Interv Radiol 2019: 30: 1303–9. doi: 10.1016/j.jvir.2018.12.022 GuiuB HincapieG ThompsonL WuY BoulinM CassinottoC An in vitro evaluation of four types of drug-eluting embolics joaded with idarubicin J Vasc Interv Radiol 2019 30 1303 9 10.1016/j.jvir.2018.12.022 Open DOISearch in Google Scholar

12. Favelier S, Boulin M, Hamza S, Cercueil JP, Cherblanc V, Lepage C, et al. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: First experience. Cardiovasc Intervent Radiol 2013; 36: 1039–46. doi: 10.1007/s00270-012-0532-8 FavelierS BoulinM HamzaS CercueilJP CherblancV LepageC Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: First experience Cardiovasc Intervent Radiol 2013 36 1039 46 10.1007/s00270-012-0532-8 Open DOISearch in Google Scholar

13. Guiu B, Schmitt A, Reinhardt S, Deltenre P, Denys A, Lepida A, et al. Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics. J Vasc Interv Radiol 2015; 26: 262–70. doi: 10.1016/j.jvir.2014.08.021 GuiuB SchmittA ReinhardtS DeltenreP DenysA LepidaA Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics J Vasc Interv Radiol 2015 26 262 70 10.1016/j.jvir.2014.08.021 Open DOISearch in Google Scholar

14. Boulin M, Hillon P, Cercueil JP, Raoul JL, Lepage C, Barbare JC, et al. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther 2014; 39: 1301–13. doi: 10.1111/apt.12776 BoulinM HillonP CercueilJP RaoulJL LepageC BarbareJC Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial Aliment Pharmacol Ther 2014 39 1301 13 10.1111/apt.12776 Open DOISearch in Google Scholar

15. Guiu B, Chevallier P, Assenat E, Barbier E, Merle P, Bouvier A, et al. Idarubicin-loaded beads for chemoembolization of hepatocellular carcinoma: the IDASPHERE II single-arm phase II trial 2019; 291: 801–8. doi: 0.1148/radiol.2019182399 GuiuB ChevallierP AssenatE BarbierE MerleP BouvierA Idarubicin-loaded beads for chemoembolization of hepatocellular carcinoma: the IDASPHERE II single-arm phase II trial 2019 291 801 8 doi: 0.1148/radiol.2019182399 Search in Google Scholar

16. Guiu B, Jouve JL, Schmitt A, Minello A, Bonnetain F, Cassinotto C, et al. Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: the LIDA-B phase I trial. J Hepatol 2018; 68: 1163–71. doi: 10.1016/j.jhep.2018.01.022. GuiuB JouveJL SchmittA MinelloA BonnetainF CassinottoC Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: the LIDA-B phase I trial J Hepatol 2018 68 1163 71 10.1016/j.jhep.2018.01.022. Open DOISearch in Google Scholar

17. Common Terminology Criteria for Adverse Events v. 5.0 [internet]. [cited 2024 Jan 3]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf Common Terminology Criteria for Adverse Events v. 5.0 [internet]. [cited 2024 Jan 3]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf Search in Google Scholar

18. Lencioni R, Llovet J. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52–60. doi: 10.1055/s-0030-1247132 LencioniR LlovetJ Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 2010 30 52 60 10.1055/s-0030-1247132 Open DOISearch in Google Scholar

19. Guiu B, Hincapie G, Thompson L, Wu Y, Boulin M, Cassinotto C, et al. An in vitro evaluation of four types of drug-eluting embolics loaded with idarubicin. J Vasc Interv Radiol 2019; 30: 1303–9. doi: 10.1016/j.jvir.2018.12.022. GuiuB HincapieG ThompsonL WuY BoulinM CassinottoC An in vitro evaluation of four types of drug-eluting embolics loaded with idarubicin J Vasc Interv Radiol 2019 30 1303 9 10.1016/j.jvir.2018.12.022. Open DOISearch in Google Scholar

20. de Baere T, Guiu B, Ronot M, Chevallier P, Sergent G, Tancredi I, et al. Real life prospective evaluation of new drug-eluting platform for chemoembolization of patients with hepatocellular carcinoma: PARIS registry. Cancers 2020; 12: 3405. doi: 10.3390/cancers12113405 de BaereT GuiuB RonotM ChevallierP SergentG TancrediI Real life prospective evaluation of new drug-eluting platform for chemoembolization of patients with hepatocellular carcinoma: PARIS registry Cancers 2020 12 3405 10.3390/cancers12113405 Open DOISearch in Google Scholar

21. Guiu B, Colombat S, Piron L, Hermida M, Allimant C, Pierredon-Foulongne MA, et al. Transarterial chemoembolization of hepatocellular carcinoma with idarubicin-loaded tandem drug-eluting embolics. Cancers 2019; 11: 987. doi: 10.3390/cancers11070987 GuiuB ColombatS PironL HermidaM AllimantC Pierredon-FoulongneMA Transarterial chemoembolization of hepatocellular carcinoma with idarubicin-loaded tandem drug-eluting embolics Cancers 2019 11 987 10.3390/cancers11070987 Open DOISearch in Google Scholar

22. Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995; 13: 2827–34. doi: 10.1200/JCO.1995.13.11.2827 AnderliniP BenjaminRS WongFC KantarjianHM AndreeffM KornblauSM Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia J Clin Oncol 1995 13 2827 34 10.1200/JCO.1995.13.11.2827 Open DOISearch in Google Scholar

23. Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, et al. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. J Hepatol 2012; 56: 609–17. doi: 10.1016/j.jhep.2011.09.012 GuiuB DeschampsF AhoS MunckF DromainC BoigeV Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads J Hepatol 2012 56 609 17 10.1016/j.jhep.2011.09.012 Open DOISearch in Google Scholar

24. Shi Z, Wang D, Jiang H, Kang T, Yi R, Cui L. Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial. Radiol Oncol 2023; 57: 70–9. doi: 10.2478/raon-2023-0001 ShiZ WangD JiangH KangT YiR CuiL Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial Radiol Oncol 2023 57 70 9 10.2478/raon-2023-0001 Open DOISearch in Google Scholar

25. Korsic S, Levasic N, Dezman R, Zupan LAL, Trotovsek B, Jansa R, et al. Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma. Radiol Oncol 2022; 56: 311–8. doi: 10.2478/raon-2022-0019 KorsicS LevasicN DezmanR ZupanLAL TrotovsekB JansaR Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma Radiol Oncol 2022 56 311 8 10.2478/raon-2022-0019 Open DOISearch in Google Scholar

26. Gomes FV, Oliveira JA, Correia MT, Costa NV, Abrantes J, Torres D, et al. Chemoembolization of hepatocellular carcinoma with drug-eluting polyethylene glycol embolic agents: single-center retrospective analysis in 302 patients. J Vasc Interv Radiol 2018; 29: 841–9. doi: 10.1016/j.jvir.2018.02.004 GomesFV OliveiraJA CorreiaMT CostaNV AbrantesJ TorresD Chemoembolization of hepatocellular carcinoma with drug-eluting polyethylene glycol embolic agents: single-center retrospective analysis in 302 patients J Vasc Interv Radiol 2018 29 841 9 10.1016/j.jvir.2018.02.004 Open DOISearch in Google Scholar

27. Lucatelli P, Ginnani Corradini L, De Rubeis G, Corona M, Saba L, Catalano C, et al. Balloon-occluded transcatheter arterial chemoembolization (b-TACE) for hepatocellular carcinoma performed with polyethylene-glycol epirubicin-loaded drug-eluting embolics: safety and preliminary results. Cardiovasc Intervent Radiol 2019; 42: 853–62. doi: 10.1007/s00270-019-02192-y LucatelliP Ginnani CorradiniL De RubeisG CoronaM SabaL CatalanoC Balloon-occluded transcatheter arterial chemoembolization (b-TACE) for hepatocellular carcinoma performed with polyethylene-glycol epirubicin-loaded drug-eluting embolics: safety and preliminary results Cardiovasc Intervent Radiol 2019 42 853 62 10.1007/s00270-019-02192-y Open DOISearch in Google Scholar

28. Aliberti C, Carandina R, Sarti D, Mulazzani L, Pizzirani E, Guadagni S, et al. Chemoembolization adopting polyethylene glycol drug-eluting embolics loaded with doxorubicin for the treatment of hepatocellular carcinoma. AJR Am J Roentgenol 2017; 209: 430–4. doi: 10.2214/AJR.16.17477 AlibertiC CarandinaR SartiD MulazzaniL PizziraniE GuadagniS Chemoembolization adopting polyethylene glycol drug-eluting embolics loaded with doxorubicin for the treatment of hepatocellular carcinoma AJR Am J Roentgenol 2017 209 430 4 10.2214/AJR.16.17477 Open DOISearch in Google Scholar

29. Fiorentini G, Sarti D, Carandina R, Mincarelli C, Candelari R, Argirò R, et al. A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma. Future Oncol 2019; 15: 695–703. doi: 10.2217/fon-2018-0425 FiorentiniG SartiD CarandinaR MincarelliC CandelariR ArgiròR A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma Future Oncol 2019 15 695 703 10.2217/fon-2018-0425 Open DOISearch in Google Scholar

30. Veloso Gomes F, de Baère T, Verset G, Coimbra É, Tovar-Felice G, Malagari K, et al. Transarterial chemoembolization with anthracyclines-loaded polyethylene glycol drug eluting microspheres for the treatment of hepatocellular carcinoma: a pooled multicentric analysis of survival in 580 patients. Cardiovasc Intervent Radiol 2023; 46: 436–46. doi: 10.1007/s00270-023-03362-9 Veloso GomesF de BaèreT VersetG CoimbraÉ Tovar-FeliceG MalagariK Transarterial chemoembolization with anthracyclines-loaded polyethylene glycol drug eluting microspheres for the treatment of hepatocellular carcinoma: a pooled multicentric analysis of survival in 580 patients Cardiovasc Intervent Radiol 2023 46 436 46 10.1007/s00270-023-03362-9 Open DOISearch in Google Scholar

31. Popovic P, Stabuc B, Jansa R, Garbajs M. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under conebeam computed tomography control. Radiol Oncol 2016; 50: 418–26. doi: 10.1515/raon-2015-0045 PopovicP StabucB JansaR GarbajsM Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under conebeam computed tomography control Radiol Oncol 2016 50 418 26 10.1515/raon-2015-0045 Open DOISearch in Google Scholar

32. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv238–55. doi: 10.1093/annonc/mdy308 VogelA CervantesA ChauI DanieleB LlovetJM MeyerT Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2018 29 iv238 55 10.1093/annonc/mdy308 Open DOISearch in Google Scholar

33. Bruix J, Reig M, Rimola J, Vilana R, Burrel M, Llovet JM, et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 2011; 54: 2238–44. doi: 10.1002/hep.24670 BruixJ ReigM RimolaJ VilanaR BurrelM LlovetJM Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques Hepatology 2011 54 2238 44 10.1002/hep.24670 Open DOISearch in Google Scholar

34. Wang H, Li B, Wang Y, Zhang J, Wu Y, Fan W, Li J. Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization. J Cancer Res Ther 2020; 16: 301–8. doi: 10.4103/jcrt.JCRT_898_19 WangH LiB WangY ZhangJ WuY FanW LiJ Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization J Cancer Res Ther 2020 16 301 8 10.4103/jcrt.JCRT_898_19 Open DOISearch in Google Scholar